News

age-related macular degeneration
NSAIDS anti-inflammatory properties may protect against AMD
A retrospective study which was published in Ophthalmology, reveals that prescription NSAID users have a lower risk of developing age-related macular degeneration.

anti-VEGF
Anti-VEGF injections may be linked to increased risk of cataracts
Several eye conditions are treated using anti-VEGF injections including retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration.

diabetic macular edema
Eylea HD receives approval for dosing interval extension
This updated dosing schedule means that wet AMD and DME patients can now have their treatment plans tailored to their individual needs.

Axpaxli
Successful Phase 3 study results for Ocular's Axpaxli wet AMD drug
Ocular Therpeutix announced successful results of their experimental drug Axpaxli in treating wet age-related macular degeneration.

AMD
New genetic risk linked to severe macular degeneration.
Researchers from the Centre of Eye Research Australia, WEHI and the University of Melbourne discovered specific genetic changes that raise the risk of severe forms of age-related macular degenerati...

age related macular degeneration
Possible link between Psorias and risk of developing age-related macular degeneration
Study findings demonstrated a link between psoriasis and both dry and wet macular degeneration.

blue light
Do blue-light intraocular lenses lower risk of wet AMD?
Very limited human study data is available in regards to the effect of long-term exposure to blue light despite it being considered a risk factor for retinal diseases.

intravitreal injections
Cancer drug may also be a possible treatment for age-related macular degeneration
Clinical trials are set to launch later this year to evaluate whether the cancer drug, PRL3-zumab, is effective in treating wet age-related macular degeneration (AMD) as well as diabetic retinopathy.

diabetes
Popular diabetes and weight loss drug linked to double the risk of developing neovascular macular degeneration
Semaglutide, a popular diabetes and weight loss drug, has been found to double the risk of developing neovascular age-related macular degeneration (nAMD) in older patients with diabetes.
